ClinicalTrials.gg
CompletedNCT03837938LDP0114Updated Apr 16, 2024Results posted

Clinical Trial of Efficacy and Safety of Levopront® 30 mg/5 ml in Patients With Dry Cough

A Phase 3 interventional study of Levopront® syrup 30 mg/5 ml and Libexin® in Cough, sponsored by Dompé Farmaceutici S.p.A. Completed at 8 sites in Russian Federation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by Dompé Farmaceutici S.p.A · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Nov 2016, registered Jan 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Primary objective:

To assess the efficacy of Levopront® in comparison with Libexin® based on daytime cough resolution rate by Day 8.

The daytime cough symptoms resolution corresponds to 0 or 1 points on the "Six-point daytime and nighttime cough assessment scale".

Secondary objectives:

Treatment effect assessment in terms of the following efficacy and safety parameters:

  • To assess the efficacy of Levopront® in comparison with Libexin® based on nighttime cough resolution rate by Day 8.
  • Daytime and nighttime cough symptoms resolution according to "Six-point daytime and nighttime cough assessment scale" by Day 4.
  • Change in severity and frequency of daytime and nighttime cough according to "Six-point daytime and nighttime cough assessment scale" on Day 4 and Day 8 from baseline on Day 1.
  • Cough intensity change according to the visual-analogue scale on Day 4 and Day 8 from baseline on Day 1.
  • Change of FEV1 on Day 8 from baseline values on Day 1.
  • Rate of Adverse events (AE) and Serious Adverse Events (SAE) of the various severity according to subjective complaints, laboratory test results, physical examination, vital signs and spirometry
Read the detailed description

This is a multicenter, open-label, randomized, clinical trial to assess the efficacy and safety of Levopront® syrup 30 mg/5 ml in comparison with Libexin® 100 mg tablets in patients suffering from dry non-productive cough caused by acute upper respiratory infection

02

Conditions studied

  • Cough

Browse trials for

03

In context

Cough

428 studies on the registry are indexed under Cough; 68 are open to participants now.

This study's enrollment of 184 is above the median of 80 across 320 interventional studies indexed under Cough.

Browse Cough studies →

Lead sponsor

Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects should meet the following inclusion criteria to be included into this clinical trial:

  1. Signed Form
  2. Male or female aged from 18 to 65 (inclusive)
  3. Dry non-productive cough as a symptom of acute upper respiratory infection (IDC codes J00-J06)
  4. Daytime cough symptom score ≥ 3 points according to the "Six-point daytime and nighttime cough assessment scale"
  5. Pre-bronchodilator ≥ 70% of the predicted values, post-bronchodilator FEV1 increase of ≤ 12% or ≤ 200 ml compared to the baseline, FEV1/FVC (Tiffeneau index) ≥ 0.7
  6. Patient's consent to follow the protocol procedures, including the completion of the patient's diary
  7. Patient's consent to use the adequate methods throughout the study period. The adequate birth control methods are as follows:

    • Oral or transdermal contraceptives
    • Condoms or diaphragms (barrier method) with spermicide
    • Intrauterine contraceptive devices

Exclusion criteria

Exclusion Criteria:

Subjects with any of the following conditions will be excluded from the study:

  1. or individual to Levodropropizine, Prenoxdiazine or additives of the study drug
  2. Hereditary fructose intolerance, glucose-lactose malabsorption, lactase deficiency, sucrose-isomaltose deficiency
  3. Tuberculosis, bronchial asthma, malignant tumors of lungs or bronchi, , severe respiratory failure (cyanosis, need for respiratory support) or other lung pathology at screening or in history
  4. Inhalation anesthesia within 3 months before screening
  5. Smoking history of more than 10 pack-years
  6. Previous use of cough medicines, ACE inhibitors or amiodarone within 30 days before screening
  7. Contraindications or inability to perform spirometry
  8. Necessity (in the Investigator's opinion) of prescribing mucolytic agents, expectorants, antibiotics or other medications prohibited by the protocol during the study
  9. Excessive mucous excretion which (in the Investigator's opinion) could be a contraindication to prescribing anti-cough medicines; decreased mucociliary function (Kartagener's syndrome, ciliary dyskinesia)
  10. Malignant tumors in the past 5 years (except for the basal cell carcinoma)
  11. Serious cardiovascular disease at the moment or within 12 months prior to screening, including: Chronic heart failure class III or IV (according to the classification of the ), severe arrhythmias requiring treatment with antiarrhythmic drugs class Ia, Ib, Ic or III, unstable angina, myocardial infarction, heart surgery and coronary arteries, serious valvular heart disease, or stroke, uncontrolled hypertension with systolic blood pressure > 180 mmHg and diastolic blood pressure > 110 mmHg, pulmonary embolism or deep vein thrombosis
  12. Gastric or duodenal ulcers, gastroesophageal reflux disease within a period of 12 months before screening
  13. Systemic disorders and connective tissue diseases that require (currently or previously) administration of systemic glucocorticosteroids, cytostatic medications or penicillamine
  14. Signs of intensive non-controlled concurrent disease, including disorders of the nervous system, endocrine system, kidneys, liver or gastrointestinal tract, which (in the Investigator's opinion) could prevent the patient's participation in the study
  15. History of alcohol or drug abuse at screening or in the past, which results in the inability of the patient to participate in the study at the Investigator's discretion
  16. Taking part in another clinical trial or use of study drug within 30 days before screening
  17. Pregnant or breast-feeding women or women planning pregnancy during the clinical trial; women of (including not sterilized operatively and in period of less than 2 years), not using appropriate methods of
  18. Inability to read or write; unwillingness to understand and follow the procedures of the study protocol; violation of the drug administration regimen or procedure execution that, at the discretion of the Investigator, can impact he results of the study or safety of the patient and interfere his further participation in the study; any other concomitant medical or serious mental conditions that make the patient unsuitable for participation in the clinical study, limit the validity of receiving an or may affect the patient's ability to participate in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
184 participants (actual)

Study arms

  • Experimental
    Levopront® syrup 30 mg/5 ml

    Levopront® (levodropropizine) syrup 30 mg/5 ml 10 ml (60 mg) t.i.d. for 7 days. The study drugs was taken 3 times a day, at intervals of at least 6 hours, between meals for 7 days.

    Drug: Levopront® syrup 30 mg/5 ml

  • Active comparator
    Libexin® 100 mg tablets

    Libexin® (prenoxdiazine) 100 mg tablets. Libexin® was administered orally, 1 tablet (100 mg) 3 times a day for 7 days.

    Drug: Libexin®

Interventions

  • DrugLevopront® syrup 30 mg/5 ml

    Drug page: Dipropizine

    The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1).

    Also known as: levodropropizine

  • DrugLibexin®

    The first study drug administration was performed at the clinical site on the day of randomization; the last study drug administration was performed in the evening before Day 8 (±1). No chewing.

    Also known as: prenoxdiazine

06

What researchers measure

Primary outcomes

  1. Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population

    Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

    Time frame: At Visit 3, Day 8

  2. Number of Participants With Daytime Cough Resolution Rate by Day 8 in the ITT Population

    Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

    Time frame: At Visit 3, Day 8

Secondary outcomes

  1. Number of Participants With Nighttime Cough Resolution Rate by Day 8 in the ITT Population

    Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The nighttime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

    Time frame: At Visit 3, Day 8

  2. Number of Participants With Daytime & Nighttime Cough Symptoms Resolution in the ITT Population

    Daytime cough ( \>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The (daytime and nighttime) cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 4 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

    Time frame: At Visit 2, Day 4

  3. Change From Baseline in Severity and Frequency of Daytime and Nighttime Cough According to "Six-point Daytime and Nighttime Cough Assessment Scale" in the ITT Population

    Daytime cough ( \>08:00 h up to 22:00 h) evaluated on a 6-point scale: 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) evaluated on a 6-point scale: 0 = no cough during the night to 5 = distressing coughs preventing any sleep.

    Time frame: Baseline, At visit 2 Day 4; at visit 3, Day 8

  4. Change From Baseline in Cough Intensity According to the Visual-analogue Scale (VAS) in the ITT Population.

    The visual-analogue scale (VAS) is a 100 mm scale which ranges from 'no cough' (0 mm) to 'the worst cough severity' (100 mm). The higher the score, the worse the outcome.

    Time frame: Baseline, At visit 2 (Day 4); at visit 3 (Day 8)

  5. Change From Baseline in Pre-bronchodilator FEV1 Values on Day 8 in the ITT Population.

    FEV1 is the Forced Expiratory Volume (in liters) in 1 second. The higher the value, the better the outcome.

    Time frame: At Visit 3 (Day 8)

  6. Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) of the Various Severity According to Subjective Complaints

    Adverse Event (AE) - any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, complaint or disorder. Serious Adverse Event (SAE) - Any adverse medical event which, irrespective of the dose of the study drug: * results in death; * is life-threatening; * requires hospitalization (initial or prolonged); * results in significant, persistent or permanent impairment or disability; or * is a congenital anomaly or birth defect * is an important medical event that may be not immediately life threatening or result in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definition above.

    Time frame: From the moment of signing Informed Consent Form (prior to administration of the first dose of the study drug) to Day 30 after the last visit of the patient or last procedure per protocol, up to day 10"

07

Results

Posted Apr 15, 2024

Participant flow

Totally, 184 patients were randomized into Levopront® (Test) and the Libexin® (Control) treatment groups: there were 92 patients in each group. All the patients completed the study according to the protocol. One patient was screen failure due to post-bronchodilator FEV1 increase.

Participant flow — Overall Study
MilestoneLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Started9292
Itt population9292
Pp population8891
Safety population9292
Completed9292
Not completed00

Outcome measures

PrimaryNumber of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population

Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

Time frame:
At Visit 3, Day 8
Reported as:
Count of participants · Participants
Number of Participants With Daytime Cough Resolution Rate by Day 8 in the PP Population
ParticipantsLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Resolved (<2)6764
Ongoing (≥2)2127
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · Difference in rates levopront®-libexin®: 5.81
PrimaryNumber of Participants With Daytime Cough Resolution Rate by Day 8 in the ITT Population

Daytime cough (\>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the day; and 5 = distressing cough most of the day. The daytime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

Time frame:
At Visit 3, Day 8
Reported as:
Count of participants · Participants
Number of Participants With Daytime Cough Resolution Rate by Day 8 in the ITT Population
ParticipantsLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Resolved (<2)7065
Ongoing (≥2)2227
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · Difference in rates levopront®-libexin®: 5.43
SecondaryNumber of Participants With Nighttime Cough Resolution Rate by Day 8 in the ITT Population

Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale") where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The nighttime cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 8 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

Time frame:
At Visit 3, Day 8
Reported as:
Count of participants · Participants
Number of Participants With Nighttime Cough Resolution Rate by Day 8 in the ITT Population
ParticipantsLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Resolved (<2)9089
Ongoing (≥2)23
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · Fisher Exact · p = >0.999
SecondaryNumber of Participants With Daytime & Nighttime Cough Symptoms Resolution in the ITT Population

Daytime cough ( \>08:00h up to 22:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) was evaluated on a 6-point scale (Six-point daytime and nighttime cough assessment scale) where 0 = no cough during the night to 5 = distressing coughs preventing any sleep. The (daytime and nighttime) cough symptoms resolution corresponds to 0 or 1 points on the 6-point scale. The lower the score the better the outcome. The rate of patients who responded to treatment (cough absents, when score is 0 or 1 at "six-point cough scale" vs. cough presents, when score is ≥ 2 at "six-point cough score") by Day 4 in the study treatment group and in the control group with a non-inferiority margin of δ = 20% is reported.

Time frame:
At Visit 2, Day 4
Reported as:
Count of participants · Participants
Number of Participants With Daytime & Nighttime Cough Symptoms Resolution in the ITT Population
ParticipantsLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Resolved (<2)2220
Ongoing (≥2)7072
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · Fisher Exact · p = =0.861
SecondaryChange From Baseline in Severity and Frequency of Daytime and Nighttime Cough According to "Six-point Daytime and Nighttime Cough Assessment Scale" in the ITT Population

Daytime cough ( \>08:00 h up to 22:00 h) evaluated on a 6-point scale: 0 = no cough during the day to 5 = distressing coughs most of the day. Night-time cough ( \>22:00 h up to 08:00 h) evaluated on a 6-point scale: 0 = no cough during the night to 5 = distressing coughs preventing any sleep.

Time frame:
Baseline, At visit 2 Day 4; at visit 3, Day 8
Reported as:
Mean · units on a scale
Change From Baseline in Severity and Frequency of Daytime and Nighttime Cough According to "Six-point Daytime and Nighttime Cough Assessment Scale" in the ITT Population
units on a scaleLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
daytime cough score at Visit 2, Day 4-1.2 ± 0.8-1.2 ± 0.6
daytime cough score at Visit 3, Day 8-2.5 ± 0.8-2.2 ± 0.7
nighttime cough score at Visit 2, Day 4-0.9 ± 0.8-1.0 ± 0.9
nighttime cough score at Visit 3, Day 8-1.9 ± 1.1-1.9 ± 1.0
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 1 sided · p = <0.001Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 2 sided · p = <0.001Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 1 sided · p = <0.001Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 1 sided · p = <0.001Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
SecondaryChange From Baseline in Cough Intensity According to the Visual-analogue Scale (VAS) in the ITT Population.

The visual-analogue scale (VAS) is a 100 mm scale which ranges from 'no cough' (0 mm) to 'the worst cough severity' (100 mm). The higher the score, the worse the outcome.

Time frame:
Baseline, At visit 2 (Day 4); at visit 3 (Day 8)
Reported as:
Mean · units on a scale
Change From Baseline in Cough Intensity According to the Visual-analogue Scale (VAS) in the ITT Population.
units on a scaleLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Visit 2, Day 4-28.9 ± 15.0-24.9 ± 15.0
Visit 3, Day 8-52.1 ± 18.1-44.6 ± 17.8
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 1 sided · p = <0.001Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 1 sided · p = <0.001Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
SecondaryChange From Baseline in Pre-bronchodilator FEV1 Values on Day 8 in the ITT Population.

FEV1 is the Forced Expiratory Volume (in liters) in 1 second. The higher the value, the better the outcome.

Time frame:
At Visit 3 (Day 8)
Reported as:
Mean · liters
Change From Baseline in Pre-bronchodilator FEV1 Values on Day 8 in the ITT Population.
litersLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
Change From Baseline in Pre-bronchodilator FEV1 Values on Day 8 in the ITT Population.0.0 ± 0.60.1 ± 0.4
Statistical analysis
  • Levopront® Syrup 30 mg/5 ml vs Libexin® 100 mg Tablets · t-test, 1 sided · p = =0.336Between groups change was tested using two sample t-test (normal data) or Mann-Whitney test (violation of normality).
SecondaryNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) of the Various Severity According to Subjective Complaints

Adverse Event (AE) - any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, complaint or disorder. Serious Adverse Event (SAE) - Any adverse medical event which, irrespective of the dose of the study drug: * results in death; * is life-threatening; * requires hospitalization (initial or prolonged); * results in significant, persistent or permanent impairment or disability; or * is a congenital anomaly or birth defect * is an important medical event that may be not immediately life threatening or result in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in the definition above.

Time frame:
From the moment of signing Informed Consent Form (prior to administration of the first dose of the study drug) to Day 30 after the last visit of the patient or last procedure per protocol, up to day 10"
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) of the Various Severity According to Subjective Complaints
ParticipantsLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
patients with AE/SAE1412
patients with SAE00
Patients with death outcome AE/SAE00
Patients with mild and moderate AE/SAE1412
Patients with severe AE/SAE00
Patients with related (possible, probable or highly probable) AE/SAE12
Patients with AE/SAE led to discontinuation00

Adverse events

Collected over At visits 1 (day 1), 2 (day 4), 3 (Day 8) and follow-up (telephon call), up to day 10. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levopront® Syrup 30 mg/5 ml0/92 (0%)0/92 (0%)14/92 (15.2%)
Libexin® 100 mg Tablets0/92 (0%)0/92 (0%)12/92 (13%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventLevopront® Syrup 30 mg/5 mlLibexin® 100 mg Tablets
HeadacheNervous system disorders5/924/92
Dry mouthGastrointestinal disorders2/924/92
Alanine aminotransferase increasedInvestigations2/921/92
Hypoaesthesia oralGastrointestinal disorders1/920/92
NauseaGastrointestinal disorders1/920/92
GastroduodenitisGastrointestinal disorders0/921/92
Abdominal painGastrointestinal disorders0/921/92
DizzinessNervous system disorders1/920/92
DysgeusiaNervous system disorders0/921/92
MalaiseGeneral disorders1/920/92

Baseline characteristics

ITT population consisted of all randomized patients from both treatment groups.

Age, Categorical
Age, Categorical(Participants)Levopront® Syrup 30 mg/5 mlLibexin® 100 mg TabletsTotal
<=18 years000
Between 18 and 65 years9292184
>=65 years000
Age, Continuous
Age, Continuous(years)Levopront® Syrup 30 mg/5 mlLibexin® 100 mg TabletsTotal
Mean40.2 ± 11.440.2 ± 13.440.2 ± 12.42
Sex: Female, Male
Sex: Female, Male(Participants)Levopront® Syrup 30 mg/5 mlLibexin® 100 mg TabletsTotal
Female6064124
Male322860
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Levopront® Syrup 30 mg/5 mlLibexin® 100 mg TabletsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9292184
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Levopront® Syrup 30 mg/5 mlLibexin® 100 mg TabletsTotal
Russia9292184
08

Study locations

8 sites
  • State Public Healthcare Institution of Moscow "City Clinical Hospital # 71 of Moscow Healthcare Department"
    Moscow, 121374, Russian Federation
  • The Laboratory of Pulmonology, State Budgetary Educational Institution of Higher Professional Education "Moscow State Medical-Stomatological University n.a. A.I. Evdokimov" under Ministry of Health of the Russian Federation (Clinical base of state budget
    Moscow, 127473, Russian Federation
  • State Budgetary Educational Institution of Higher Professional Education "Ryazan' State Medical University n.a. academician I.P. Pavlov" under Ministry of Health of the Russian Federation
    Ryazan, 390026, Russian Federation
  • "Institute of Medical Research" LLC
    Saint-Petersburg, 196084, Russian Federation
  • Saint-Petersburg State Healthcare Institution "Nikolaevskaya Hospital"
    Saint-Petersburg, 198510, Russian Federation
  • State Healthcare Institution "Regional Clinical Hospital"
    Saratov, 410053, Russian Federation
  • LLC Treatment-and-prophylactic institution on the "Smolensk clinic"
    Smolensk, 214016, Russian Federation
  • State Autonomous Healthcare Institution of Yaroslavl Region "Clinical Hospital of Emergency care n.a. N.V. Solovyev"
    Yaroslavl, 150003, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2018, 15 months.

Results were first posted in Apr 2024, 6 years 1 month after primary completion.

Of 18 phase 3 interventional studies under Cough, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Feb 12, 2019
StartActual
Nov 9, 2016
Primary completionActual
Mar 6, 2018
CompletionActual
Jul 31, 2018
Results first posted
Apr 15, 2024
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03837938
Responsible party
Sponsor
First posted
Feb 12, 2019
Start date
Nov 9, 2016
Primary completion
Mar 6, 2018
Completion
Jul 31, 2018
Results posted
Apr 15, 2024
Last update
Apr 16, 2024

Study contacts

Federico Saibene, MD
study director · Dompé SpA Milan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dipropizine

Start the discussion